Lead the way with clinically proven technology

HeartLogic Clinical Data

Explore the clinical data and real-world evidence showing how HeartLogic Heart Failure Diagnostic changes the future of electrophysiology and allows you to do things you couldn’t do before.

Time Course of HF Decompensation¹

Emulating Clinical Assessment via Physiologic Sensor Monitoring

Electrophysiology Insights

HeartLogic uses automated intelligence to streamline your ability to see each patient’s physiologic response to arrhythmic and pacing changes.

Relationship Between Atrial Fibrillation and HeartLogic Index²

HeartLogic May Detect Sub-Optimal BiV Pacing and Poor Physiologic Response³

HeartLogic May Identify Patients Vulnerable to RV Pacing⁴


Phase I of the MANAGE-HF study enrolled 200 patients implanted with a CRT-D or ICD enabled with HeartLogic. The study found that HeartLogic was safely integrated into clinical practice and associated with lower natriuretic peptide levels and hospitalization rates.⁶

Of HeartLogic Index

NTproBNP Levels

In HF Hospitalizations Associated with HeartLogic*

*Compared with pre-study hospitalization rate (12 months).

MultiSENSE Study Results⁷

The MultiSENSE study assessed more than 900 patients and validated that the HeartLogic algorithm provides a sensitive and timely predictor of impending heart failure decompensation.

in Detecting Heart Failure Events

Advance Notice of Worsening Heart Failure

Per Patient Per Year

Real-World Evidence

In real-world analyses of nearly 500 patients across four studies, HeartLogic was shown to provide consistent heart failure detection performance with low unexplained alert rates.

Real-World Results Compared to Validation Data Set

MultiSENSE⁷ (Validation Data Set) 70% 1.47
Capucci et al.² (ESC HF 2019) 100%* 0.41
Santini et al.⁸ (Clin Card 2020) 69%* 0.37
RE-HEART Phase I⁹ (ESC HF 2020) N/A 0.25
RE-HEART Phase II¹⁰ (ESC HF 2020) N/A 0.13

Highlights from Real-World Studies

Provided New Information to Clinicians⁸

by a Median of 12 Days²

by a Median of 38 Days²

HeartLogic reduces hospitalisations for decompensated heart failure and significantly reduces the costs per patient for the healthcare system, as described in the Heggermont et al publication.¹¹

Results from APAF-Mortality Clinical Trial CRT Ablate and Pace – Proven Best Option

Professor Michele Brignole and Isabelle van Gelder reviewed clinical data coming from the APAF-CRT Mortality trial which has made very clear that Ablation + CRT was superior to pharmacological therapy in reducing mortality in patients with permanent AF. 
These new and powerful results strengthens and supports the CRT therapy also for these indicated patients.

List of products

Stay Up to Date

Sign up for periodic emails and receive a HeartLogic fact sheet to share with your patients’ care teams.

Icon with envelope


Your extraordinary talent. Our extraordinary technology. Explore the Boston Scientific CRT-Ds and ICDs that feature HeartLogic.


1. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009 Dec;6(4):287-92. doi: 10.1007/s11897-009-0039-z.
2. Capucci A, Healey JS. Temporal association of atrial fibrillation with device-based heart failure status in patients with CRT. Oral presentation and LBCT presented at: EHRA Congress; March 2019, Lisbon, Portugal.
3. Varma N, Cao M, Schloss EJ, Ahmed R, Stolen C, Boehmer JP. Progressive worsening in device base failure sensors measurements are associated with sub-optimal BiV pacing percentages in CRT-D patients. J Heart Fail. 2019;21(Suppl. S1):370. doi: 10.1002/ejhf.1488
4. Varma N, Stein KM, Thakur PH, Jones PW, Ahmed R, J Boehmer J. Multiparametric analysis of device based physiological sensors may identify ICD patients reacting adversely to right ventricular pacing [abstract]. Heart Rhythm. 2019;16(5):S58-S59.
5. Multiple Cardiac Sensors for the Management of Heart Failure (MANAGE-HF). https://clinicaltrials.gov/ct2/show/NCT03237858
6. Hernandez AF, Albert N, Allen L, et al. Multiple cardiac sensors for management of heart failure (MANAGE-HF) Phase I results. Abstract presented at: European Society of Heart Failure 2021 World Congress on Acute Heart Failure: June 29-July 1, 2021. Virtual.
7. Boehmer JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Fail. 2017 Mar;5(3):216-25. doi: 10.1016/j.jchf.2016.12.011.
8. Santini L, D’Onofrio A, Russo AD, et al. Prospective evaluation of the multisensor HeartLogic algorithm for heart failure monitoring. Clin Card. 2020;43(7):691-697. doi: 10.1002/clc.23366
9. De Juan Baguda J, Gavira Gomex JJ, Pachó Iglesias M, et al. Preliminary results of the Spanish multicentric HeartLogic (RE-HEART) registry: a blinded analysis. Abstract presented virtually at: ESC-HFA Congress 2020.
10. De Juan Baguda J, Gavira Gomex JJ, Pachó Iglesias M, et al. Preliminary results of the Spanish multicentric HeartLogic (RE-HEART) registry: adoption of an alert-based heart failure management approach. Abstract presented virtually at: ESC-HFA Congress 2020.
11. Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients, Heggermont et all, ESC Heart Failure (2021) Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13252
*The HeartLogic Index and Alert were validated using data from the MultiSENSE study; however, HeartLogic’s impact on clinical outcome has not been established. Establishment of the impact will require a post market trial designed specifically to study clinical outcomes directly related to the use of this feature.


The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.